“Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s10. doi:10.25251/skin.1.supp.9.